Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II open-label single-center study of GLR2007 in advanced solid tumors with central nervous system involvement
CTR20212487Phase 2Active
- Sponsor
- Gannex Pharma Co., Ltd.
- Start
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of crozbaciclib in glioblastoma (GBM), brain metastases, central nervous system tumor, breast cancer, non-small cell lung cancer (NSCLC), sponsored by Gannex Pharma Co., Ltd.. Started Oct 2021; status: active.
02
Drugs
crozbaciclib
03
Conditions
glioblastoma (GBM)brain metastasescentral nervous system tumorbreast cancernon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20212487.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212487.